These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21967627)

  • 21. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
    Ryan C; Kirby B; Collins P; Rogers S
    Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
    Gordon KB; Langley RG; Leonardi C; Toth D; Menter MA; Kang S; Heffernan M; Miller B; Hamlin R; Lim L; Zhong J; Hoffman R; Okun MM
    J Am Acad Dermatol; 2006 Oct; 55(4):598-606. PubMed ID: 17010738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic.
    Adenubiova E; Arenberger P; Gkalpakioti P; Arenbergerova M; Jircikova J; Dolezal T; Gkalpakiotis S
    J Dermatolog Treat; 2018 Sep; 29(6):579-582. PubMed ID: 29307245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
    Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
    Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment.
    Taniguchi T; Noda S; Takahashi N; Yoshimura H; Mizuno K; Adachi M
    J Eur Acad Dermatol Venereol; 2013 Nov; 27(11):1444-7. PubMed ID: 22702802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
    Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H
    Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
    Papp K; Menter A; Poulin Y; Gu Y; Sasso EH
    J Eur Acad Dermatol Venereol; 2013 May; 27(5):634-42. PubMed ID: 22429586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
    Kimball AB; Yu AP; Signorovitch J; Xie J; Tsaneva M; Gupta SR; Bao Y; Mulani PM
    J Am Acad Dermatol; 2012 Feb; 66(2):e67-76. PubMed ID: 21616560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
    Menting SP; van Lümig PP; de Vries AC; van den Reek JM; van der Kleij D; de Jong EM; Spuls PI; Lecluse LL
    JAMA Dermatol; 2014 Feb; 150(2):130-6. PubMed ID: 24352354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
    J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients.
    Ardigò M; Giuliani A; de Felice C; Mastroianni A; Berardesca E
    J Drugs Dermatol; 2008 Oct; 7(10):935-9. PubMed ID: 19112756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.
    Bissonnette R; Bolduc C; Poulin Y; Guenther L; Lynde CW; Maari C
    J Am Acad Dermatol; 2010 Aug; 63(2):228-34. PubMed ID: 20494479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
    Menter A; Tyring SK; Gordon K; Kimball AB; Leonardi CL; Langley RG; Strober BE; Kaul M; Gu Y; Okun M; Papp K
    J Am Acad Dermatol; 2008 Jan; 58(1):106-15. PubMed ID: 17936411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.
    Lecluse LL; Driessen RJ; Spuls PI; de Jong EM; Stapel SO; van Doorn MB; Bos JD; Wolbink GJ
    Arch Dermatol; 2010 Feb; 146(2):127-32. PubMed ID: 20157022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of psoriasis with adalimumab.
    Pitarch G; Sanchez-Carazo JL; Mahiques L; Perez-Ferriols MA; Fortea JM
    Clin Exp Dermatol; 2007 Jan; 32(1):18-22. PubMed ID: 17305904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
    Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
    Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.
    Takahashi H; Tsuji H; Ishida-Yamamoto A; Iizuka H
    J Dermatol; 2013 Jan; 40(1):39-42. PubMed ID: 23039179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.
    Armesto S; Coto-Segura P; Mayorga J; Illaro A; Santos-Juanes J
    J Dermatolog Treat; 2015 Feb; 26(1):49-53. PubMed ID: 24552591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.